Covid-19 controversies: the tocilizumab chapter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 4 syntheses or guidelines pooled it.

1. Signals were broadly positive for months, but never definitive: the tocilizumab story.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022
   Pooled it
2. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysis.Scientific reports · 2021
   Pooled it
3. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2021
   Pooled it
4. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era.Frontiers in medicine · 2021
   Pooled it
5. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.Immunity, inflammation and disease · 2022
   Trial
6. Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: A systematic review andPreventive medicine reports · 2023
   Review
7. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.Open forum infectious diseases · 2022
   Article
8. The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.Frontiers in pharmacology · 2021
   Review
9. Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.PloS one · 2021
   Article
10. Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis.Frontiers in immunology · 2021
    Article
11. Public perceptions of the association between drug effectiveness and drug novelty in France during the COVID-19 pandemic.Therapie
    Article
12. Efficacy of tocilizumab in COVID-19: A review of the current evidence.Science progress
    Article

Corrections and comments

• Comment on
  Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.2021

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as